The development of diffuse panbronchiolitis during the treatment with long-term, low-dose clarithromycin for chronic sinusitis

J Infect Chemother. 2019 Feb;25(2):147-150. doi: 10.1016/j.jiac.2018.07.011. Epub 2018 Aug 7.

Abstract

Diffuse panbronchiolitis (DPB) is a progressive inflammatory airway disease characterized by a chronic cough, copious sputum expectation, dyspnea, and chronic sinusitis. Owing to the long-term treatment of low-dose macrolides, the prognosis has been remarkably improved. However, in some cases, patients are refractory to macrolides, and the subsequent treatment strategies are controversial. We herein present a patient with the onset of DPB during treatment with long-term, low-dose clarithromycin (CAM) for chronic sinusitis who was successfully treated by switching to long-term treatment with normal-dose CAM. We should recognize that DPB may develop in patients with chronic sinusitis despite treatment with a long-term, low-dose macrolide. We also propose that increasing the dose of macrolide may be a useful strategy for treating refractory patients.

Keywords: Chronic sinusitis; Diffuse panbronchiolitis; Low-dose clarithromycin; Refractory to macrolide.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / therapeutic use*
  • Bronchiolitis*
  • Chronic Disease
  • Clarithromycin / adverse effects
  • Clarithromycin / therapeutic use*
  • Haemophilus Infections*
  • Humans
  • Male
  • Sinusitis / drug therapy*

Substances

  • Anti-Bacterial Agents
  • Clarithromycin

Supplementary concepts

  • Diffuse panbronchiolitis